ClinicalTrials.gg
Not yet recruitingNCT07939217UVEOMICSUpdated Nov 16, 2026

Collection and Storage of Biological Samples From Patients Affected by Uveitis for Immunological and Multi-omic Studies

An observational study in Uveitis, sponsored by IRCCS Ospedale San Raffaele. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by IRCCS Ospedale San Raffaele · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

Uveitis is a group of eye diseases that cause inflammation and may lead to vision loss. The biological processes responsible for these diseases are not fully understood, particularly in rare forms of uveitis.

The purpose of UVEOMICS is to collect and store biological samples and clinical information from adults with infectious or non-infectious uveitis, including rare inflammatory eye diseases known as white dot syndromes. Researchers will study these samples to better understand the causes of eye inflammation and identify biological markers that may help improve diagnosis, monitor disease activity, predict relapses, and guide future treatments.

The study plans to enroll approximately 2,000 adults, including 1,500 patients with uveitis and 500 individuals undergoing cataract surgery who will serve as a comparison group.

Participants may provide blood samples and small samples of fluid from inside the eye (aqueous humor or vitreous fluid), when appropriate. Samples and clinical information may be collected at different stages of the disease and during follow-up visits. Biological samples will be stored for future research and analyzed together with clinical findings and eye imaging results.

This is an observational study. Participation will not change the medical care or treatment participants receive.

02

Conditions studied

  • Uveitis

Browse trials for

Keywords

  • Uveitis
03

In context

Uveitis

300 studies on the registry are indexed under Uveitis; 32 are open to participants now.

This study's planned enrollment of 200 is above the median of 107 across 104 observational studies indexed under Uveitis.

Browse Uveitis studies →

Lead sponsor

IRCCS Ospedale San Raffaele is the lead sponsor of 37 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include approximately 2,000 adults recruited at the IRCCS Ospedale San Raffaele in Milan, Italy.

Approximately 1,500 participants will be patients diagnosed with infectious or non-infectious uveitis, including rare inflammatory eye diseases known as white dot syndromes. An additional 500 participants will be adults without uveitis undergoing elective cataract surgery, who will serve as a comparison group.

Participants will be recruited consecutively during routine outpatient visits, hospital admissions, and diagnostic or surgical procedures. Patients with uveitis may provide biological samples at different stages of their disease, including active inflammation, remission, and relapse.

Recruitment will be non-probabilistic and will include eligible adults regardless of sex or ethnicity who provide written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patients with uveitis:

Age 18 years or older.

Clinical diagnosis of infectious or non-infectious uveitis (anterior, intermediate, posterior, or panuveitis), including rare white dot syndromes such as multiple evanescent white dot syndrome (MEWDS), punctate inner choroidopathy (PIC), idiopathic multifocal choroiditis (iMFC), acute zonal occult outer retinopathy (AZOOR), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), and serpiginoid chorioretinitis.

Ability to understand and provide written .

Willingness to provide biological samples (blood and/or aqueous humor and/or vitreous humor, when clinically indicated) and associated clinical information.

Exclusion criteria

Exclusion Criteria:

Age younger than 18 years.

Severe systemic conditions that make biological sample collection unsafe, such as uncontrolled diabetes, systemic infections, or inability to be seated at the slit lamp.

Inability to provide valid .

Refusal to participate or withdrawal of informed consent.

Pregnancy or breastfeeding if these conditions contraindicate the planned biological sampling.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • uveitis patients

    uveitis patients

06

What researchers measure

Primary outcomes

  1. Number of biological samples collected and stored in the UVEOMICS biobank

    The total number of biological samples (blood, aqueous humor, and vitreous humor, when clinically available) collected, processed, and stored from enrolled participants for future immunological and molecular research. Samples will be linked to clinical and imaging data and may be collected at different stages of disease activity.

    Time frame: Throughout the study period (approximately 6 years).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2030, 48 months later.

Of 32 observational studies under Uveitis, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 143. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Nov 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939217
Lead sponsor
IRCCS Ospedale San Raffaele
Responsible party
Maria Vittoria Cicinelli (md, IRCCS Ospedale San Raffaele) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Maria Vittoria Cicinelli
Contact
cicinelli.mariavittoria@hsr.it
+3902264332648

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion